Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

NCT05388773 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Oropharynx Cancer

Interventions

PROCEDURE: therapeutic conventional surgery
OTHER: laboratory biomarker analysis
OTHER: quality-of-life assessment
RADIATION: intensity-modulated radiation therapy
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Heath Skinner